Consequently, lincRNA-COX2 may modulate the progression of PAH via the miR-let-7a/STAT3 pathway, which holds substantial importance for the investigation of targeted therapies for PAH (Cheng et al. 2020). This evidence concerns the gene STAT3 and pulmonary arterial hypertension.